In the United States, the most common of the aggressive non-Hodgkin lymphomas (NHLs) is diffuse large B-cell lymphoma (DLBCL), which accounts for between 22% and 24% of newly diagnosed B-cell NHL cases.1 Although DLBCL can affect children and young adults, it is most commonly diagnosed in individuals between the ages of 65 and 74 years, with a median age at diagnosis of 66 years.2,3 Given the aggressive nature of DLBCL, patients often present with lymphadenopathy, extranodal involvement, and other constitutional symptoms thatrequire immediate treatment.1

The treatment spectrum for DLBCL has expanded significantly in recent years, particularly for patients with relapsed or refractory (R/R) disease. Mechanisms of action differ greatly among agents, reflecting the complex pathophysiology and genetic variations of the disease. This article reviews the advances in DLBCL understanding that have led to the approval of new agents andsubsequent utilization of new mechanisms.

The current standards of care for first-line DLBCL treatment include the combination chemoimmunotherapy regimen of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP). The varying numbers of cycles and use in combination with or without radiotherapy (RT) depends upon the stage of disease at presentation.1 The addition of rituximab to CHOP was associated with a 2-year event-free survival of 57% in elderly patients in a 2002 randomized trial (LNH-98.5), which, along with results of other trials, led to the FDA approval of this combination therapy.4,5 Although durable remission can be achieved with R-CHOP in about 60% of patients, its use has resulted in poorer long-term outcomes for patients with double-hit andtriple-hit lymphomas (DHL and THL).1

In 2007, the International Harmonization Project issued guidelines on malignant lymphoma response criteria, defining relapsed disease as consisting of new lesions greater than 1.5 cm in any axis during or after the completion of therapy or a 50% or greater increase in the sum of the product of diameters of a previously involved node(s) or other lesion(s).6 The authors also defined refractory, or progressive, disease as entailing a 50% or greater increase in the size of a lymph node with a prior short-axis diameter of less than 1.0 cm to a size of 1.5 cm 1.5 cm (or a long-axis size of > 1.5 cm).6

For patients with R/R disease, high-dose chemotherapy and autologous stem cell transplant (ASCT) may offer the chance for cure, but several factors may limit the utility of this approach. For example, in the treatment of patients with MYC-positive R/R DLBCL, ASCT is considered controversial because it has produced poorer outcomes in patients with DHL.1 Additionally, patients who are older or have comorbidities may be inappropriate candidates for this approach,7 and patients with disease that is unresponsive to second-line chemotherapy may have poorer prognoses (ie, poorer rates of long-term survival) and incur added toxicity from the chemotherapy.7 Even when including patients who undergo high-dose, salvage chemotherapy and subsequent ASCT, patients with R/R DLBCL have a 1-year survival rate of 28%.1 Hence, in a search for improved outcomes in the R/R setting, clinical studies have focused on DLBCL subtypes, especially in those ineligible for transplant or who have relapsed following transplant.1

Another option for patients in the relapsed setting is chimeric antigen receptor (CAR) T-cell therapy, which entails the genetic modification of autologous T cells via cloned DNA plasmids carrying a viral recombinant vector in addition to T-cell receptor-expressing genes. CAR T-cell therapy plays an important role in the R/R DLBCL setting, with reported 2-year remissions and a complete response (CR) rate in 40% of patients and 25% DHL/THL patients.1 Other therapeutic classes that have been explored for DLBCL include phosphoinositide 3-kinase (PI3K) inhibitors, B-cell lymphoma 2 (BCL2) inhibitors, and checkpoint inhibitors.1,8-10

Given reduced survival in patients who are unresponsive to subsequent lines of therapy and the toxicity involved, a great need exists for novel agents in the R/R DLBCL setting. Recent entrants to the R/R DLBCL treatment landscape include the antibody-drug conjugate (ADC) polatuzumab vedotin-piiq, the selective inhibitor of nuclear export, selinexor, and the monoclonal antibody tafasitamab-cxix (TABLE 111-20).

Polatuzumab vedotin-piiq was approved by the FDA in 2019 and is indicated in combination with bendamustine and rituximab in adults with RR DLBCL not otherwise specified, following at least 2 previous therapies.11 It is an ADC wherein the monoclonal antibody is linked to an antimitotic agent, monomethyl auristatin E (MMAE). The ADC targets the B-cell surface protein CD79B and, after binding to the surface protein, is internalized by the cell. Lysosomal enzymes then cleave the link between the antibody and MMAE, the latter of which binds microtubules, thereby inhibiting cell division and inducing apoptosis.11

A 2020 phase 1b/2 study (NCT02257567) randomized patients with R/R DLBCL who were ineligible for ASCT to receive polatuzumab vedotin-piiq with bendamustine and rituximab (pola-BR) or bendamustine and rituximab (BR) alone.12 The phase 2 primary end point was CR; secondary end points included overall response rate (ORR) at end of treatment, superior overall response, duration of response (DOR), and progression-free survival (PFS) assessed per independent review committee (IRC).12 With a median follow-up of 22.3 months, the CR was significantly higher in the pola-BR group (40% vs 17.5% in the BR group; P = .026).12 Overall survival rate was also significantly higher in the pola-BR group (12.4 vs 4.7 months in the BR group; HR, 0.42; 95% CI, 0.24-0.75; P = .002).12 Similarly, median PFS was significantly longer at 9.5 months in the pola-BR group compared with 3.7 months in the BR group (HR, 0.36; 95% CI, 0.21-0.63; P < .001).12 Also, DOR was longer at 12.6 months in the pola-BR group vs 7.7 months in the BR group (HR, 0.47; 95% CI, 0.19-1.14).12 Finally, the pola-BR group had a 58% reduction in risk of death compared with the BR group (HR, 0.42; 95% CI, 0.24-0.75; P = .002).12 In terms of safety, grade 3/4 anemia, neutropenia, thrombocytopenia, and peripheral neuropathy occurred more frequently in the pola-BR group than in the BR group.12 Polatuzumab vedotin-piiq was deemed an effective agent that might provide a therapeutic option for patients with R/R DLBCL who were not ideal candidates for CAR T-cell therapy.12

In 2020, selinexor was approved by the FDA for use in adult patients with R/R DLBCL (including follicular lymphoma-derived DLBCL) after at least 2 lines of systemic treatment.13 Selinexor inhibits nuclear export of tumor suppressor proteins by blocking exportin 1.13

The FDA approval was based on results of the open-label single-arm phase 2 SADAL trial (NCT02227251), which included patients 18 years or older with DLBCL (based on pathologic confirmation) with an Eastern Cooperative Oncology Group (ECOG) score of 2 or less, who had 2 to 5 lines of prior therapy, and who had progressed following or were ineligible for ASCT.14 The primary end point of the SADAL trial was ORR (comprising patients with CR or PR per 2014 Lugano criteria), with secondary end points consisting of DOR and disease control rate.14 Patients received the 60-mg oral selinexor on the first and third day of each week until disease progression or unacceptable toxicity occurred.14

The updated phase 2b ORR was 28.3% with a disease control rate of 37% (95% CI, 28.6-46.0). Of 36 responders, CRs were reported in 13 evaluable patients and PRs were reported in 23 patients. At a median follow-up of 11.1 months, the median DOR was 9.3 months (95% CI, 4.8-23.0). For those with a CR, median DOR was 23.0 months (95% CI, 10.4-23.0); median DOR was 4.4 months for those with a PR (95% CI, 2.0not evaluable).14,15 To address potential differences by subtype, the SADAL trial also included a subgroup analysis of patients with the germinal center B-cell (GCB)like subtype (n = 59), which demonstrated an ORR of 33.9%, a 14% CR rate, and a 20% PR rate, whereas the patients with a non-GCB subtype (n = 63) had an ORR of 20.6%. At the time of data cutoff, 7%(n = 9) of patients showed continuing response.14,15 The SADAL trial also included 5 patients with the unclassified subtype, in 1 of whom a CR was achieved and in 2 of whom a PR was achieved.15With respect to safety, 98% of patients in the SADAL trial had at least 1 treatment-emergent adverse event (TEAE). The most frequent grade 3/4 events were thrombocytopenia, neutropenia, anemia, fatigue, hyponatremia, and nausea.14 Among serious AEs affecting 48% of patients, the most common were pyrexia, pneumonia, and sepsis.14 Gastrointestinal AEs werereported in 80% of patients, hyponatremia in 61%, and central neurologic events (which included dizziness and altered mental status) in 25%.16 Trial investigators concluded that selinexor improved survival considerably and that it presented a nonchemotherapy oral option for patients with R/R DLBCL.14

Tafasitamab-cxix is a CD19-targeting monoclonal antibody that gained FDA approval in 2020 for use with lenalidomide in adults with R/R DLBCL who are ineligible for ASCT, including patients with low-grade lymphoma derived DLBCL.17 Tafasitamab-cxix binds to the pre-B and mature B-lymphocyte surface antigen CD19, which is expressed in DLBCL and other B-cell malignancies.17 Tafasitamab-cxix, once bound to CD19, facilitates B-lymphocyte lysis via apoptosis and immune effector mechanisms that encompass antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.17

The FDA approval of tafasitamab-cxix was based on data from the phase 2, single-arm, multicenter, open-label L-MIND trial (NCT02399085).17,18 The L-MIND trial included patients 18 years or older with R/R DLBCL who had received 1 to 3 previous therapies ( 1 of which incorporated a CD20-directed regimen), had an ECOG score of 0 to 2, and were ASCT ineligible.18 Patients were administered tafasitamab-cxix and lenalidomide in 28-day cycles and continued to receive tafasitamab-cxix every 2 weeks after cycle 12 until disease progression.18 Objective response rate (ie, PR and CR) was the primary end point per IRC, which implemented PET imaging; secondary end points included investigator-assessed objective response rate, DOR, OS, PFS, biomarker analyses, and safety.18 Eighty patients were included in the full analysis set (FAS), receiving tafasitamab-cxix plus lenalidomide.18 Of the FAS, the objective response rate was 60.0% (95% CI, 48.4%-70.8%) and the CR rate was 42.5% (34/80).18 The rate of patients achieving a 12-month DOR rate was comparable across subgroups, with 70.5% of patients who received 1 prior line of therapy achieving a 12-month DOR (95% CI, 47.2%-85.0%) and 72.7% of patients who had 2 or more prior lines of therapy achieving a 12-month DOR (95% CI, 46.3%-87.6%).18

Outcomes in patients with GCB DLBCL (n = 37) were promising, with an objective response rate of 48.6%, a 12-month DOR rate of 53.5%, and a 12-month OS rate of 65.4% (based upon the Hans algorithm). Outcomes in patients with non-GCB DLBCL (n = 21) were an improvement over those with the GCB subtype, with an objective response rate of 71.4%, a 12-month DOR rate of 83.1%, and a 12-month OS rate of 84.2%.18 IRC-evaluated data from a 2-year follow up of the L-MIND trial showed an objective response rate of 58.8% (47/80) and CR rate of 41.3% (33/80).19 The 2-year follow up data also showed a median DOR of 34.6 months, with a 31.6-month median OS and a 16.2-month median PFS.19

Safety data from the preliminary L-MIND trial results showed that the most frequent TEAEs (of any grade) were neutropenia (48%), thrombocytopenia (32%), anemia (31%), diarrhea (30%), pyrexia (22%), and asthenia (20%).20 A lenalidomide dose reduction was required in 42% of patients; 72% of patients could remain on daily lenalidomide at 20 mg or higher.20 Trial investigators concluded that the combination of tafasitamab-cxix and lenalidomide was well tolerated and did not lead to compounded AEs.20

The promising data from recent trialsparticularly from their DLBCL subtype based subgroupsunderscore the importance of understanding the unique prognoses and responses that these subtypes confer on patient outcomes. The establishment of DLBCL subtypes as prognostic and therapeutic response factors has fueled a search for more specific molecular targets in the disease process. In addition, the importance of subtype characterization is evidenced by ongoing diagnostic assay development (for use in conjunction with immunohistochemistry). As exemplified by the patient populations in these trials, new therapeutic options with distinct mechanisms of actions are needed for patients with R/R DLBCL who are ineligible for ASCT. Multiple studies of targeted agents in the R/R DLBCL setting are under way that include CAR T-cell, bispecific T-cell engager, programmed death receptor 1 (PD-1) inhibitor, and BCL2 inhibitor therapies.1 Continued development of clinically applicable diagnostics holds promise for improved prognostic capability and assessment of therapeutic response. With improved diagnostics, further elucidation of DLBCL-driver mutations can continue to provide additional DLBCL subtype-specific options and, hence, more treatments tailored to individual patients.

References1. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604-616. doi:10.1002/ajh.254602. Diffuse large B-cell lymphoma. Lymphoma Research Foundation. Accessed October 12, 2020. https://lymphoma.org/aboutlymphoma/nhl/dlbcl/3. Cancer stat facts: NHL diffuse large B-cell lymphoma (DLBCL). National Cancer Institute. Accessed October 12, 2020. https://seer.cancer.gov/statfacts/html/dlbcl.html4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. doi:10.1056/NEJMoa0117955. Rituxan plus CHOP approved for diffuse large B-cell lymphoma. Cancer Network. February 28, 2006. Accessed November 6, 2020. https://www.cancernetwork.com/view/rituxan-plus-chop-approved-diffuse-large-b-cell-lymphoma6. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. doi:10.1200/JCO.2006.09.24037. Elstrom RL, Martin P, Ostrow K, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk. 2010;10(3):192-196. doi:10.3816/CLML.2010.n.0308. Oki Y, Kelly KR, Flinn I, et al. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. Haematologica. 2017;102(11):1923-1930. doi:10.3324/haematol.2017.1728829. Ansell S, Gutierrez ME, Shipp MA, et al. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood.2016; 128(22):183. doi:10.1182/blood.V128.22.183.18310. Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698-2704. doi:10.1200/JCO.2015.65.978911. POLIVY. Prescribing information. Genentech, Inc; 2020. Accessed October 22, 2020. https://www.gene.com/download/pdf/polivy_prescribing.pdf12. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155-165. doi:10.1200/JCO.19.0017213. XPOVIO. Prescribing information. Karyopharm Therapeutics, Inc; 2020. Accessed October 22, 2020. https://www.karyopharm.com/wp-content/uploads/2019/07/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf14. Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511-e522. doi:10.1016/S2352-3026(20)30120-415. Karyopharm reports updated data from the phase 2b SADAL study at the 2019 International Conference on Malignant Lymphoma. News release. Karyopharm. June 19, 2019.Accessed June 28, 2020. https://www.globenewswire.com/news-release/2019/ 06/19/1871363/0/en/Karyopharm-Reports-Updated-Data-from-the-Phase-2b-SADAL-Study-at-the-2019-International-Conference-on-Malignant-Lymphoma.html16. FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma. News release. FDA. June 22, 2020. Accessed June 28, 2020. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma17. Monjuvi. Prescribing information. MorphoSys US Inc; 2020. Accessed October 22, 2020. https://www.monjuvi.com/pi/monjuvi-pi.pdf18. Duell J, Maddocks KJ, Gonzalez-Barca E, et al. Subgroup analyses from L-Mind, a phase II study of tafasitamab (MOR208) combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood. 2019;134(suppl 1):1582. doi:10.1182/blood-2019-12257319. MorphoSys and Incyte announce long-term follow-up results from L-MIND study of tafasitamab in patients with r/r DLBCL. News release. Morpho-Sys. May 14, 2020. Accessed June 26, 2020. https://www.morphosys.com/media-investors/media-center/morphosys-and-incyte-announce-long-term-follow-up-results-from-l-mind20. Salles GA, Duell J, Gonzlez-Barca E, et al. Single-arm phase II study of MOR208 combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: L-Mind. Blood. 2018;132(suppl 1):227. doi:10.1182/blood-2018-99-113399

Original post:
New Approaches to the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma - Targeted Oncology

HomeIn the last in a series on milestone anniversaries in politics and cultural history, produced with Huddersfield University, we recall the controversy generated by the first genetically modified food in Britain.

Saturday, 2nd January 2021, 6:00 am

It was only a tin of tomato puree, but it created a stink that lingered for years.

The 25th anniversary of the first genetically modified food to go on sale in a British supermarket merits scarcely a footnote in retailing history, yet it heralded a new scientific era. That same year, Dolly the sheep, the first mammal to have been successfully cloned from an adult cell, made her debut at Edinburgh University.

The cans of concentrated California puree that went on sale at Sainsburys and Safeway in February 1996 had been produced from the flavr savr tomato , a strain from which the rotting gene, not to mention most of the vowels, had been removed. The bioscience company Zeneca had spent 10 years perfecting the process, and said the result was a stronger tasting sauce that stuck better to pasta.

Critics, however, called it Frankenstein food and some threatened a boycott. The Prince of Wales said the implications of genetically modified cops were enough to send a cold chill down the spine.

The tins stayed on the shelves for three years before demand subsided and the range was withdrawn. Today, Britain remains one of the few developed nations where such crops are not grown commercially, although modified oilseed rape, soybean, cotton-seed oil, maize and sugar beet are allowed to be imported.

But it is politics, not science that is holding back the tide, according to one Yorkshire expert.

As a scientist, and taking into account the laws and safety procedures that are in place, I dont see a problem, said Dr Dougie Clarke of Huddersfield Universitys School of Applied Sciences.

They create higher yields, there is less food waste and in third world countries where growing food in arid conditions is a problem, they now have drought-resistant crops that they can grow and sustain.

The issue, he said, was that while politicians were content to be led by science in their response to illness and disease, they were less willing to listen to the arguments for genetic modification.

The British government is more worried about the publics opinion than they really should be, he said. I understand that people are concerned that these modified crops might begin to wipe out the natural variety, but there are very good control measures in place to prevent that happening.

The campaign group Genewatch UK takes the opposite view, calling for protection for plants and animals from contamination by genetically modified organisms, and a ban on activities that would compromise human rights and food security.

The argument goes far beyond crops, and as Dr Clarke pointed out, the work carried out in Edinburgh 25 years ago had been the catalyst for many important medical developments.

In 1996 we were leading the world with Dolly the sheep, and the one good thing that the British government allowed was research in stem cells, which can replace damaged tissues, whereas America banned it at one stage.

Dollys arrival on July 5 1996 was for a while one of the worlds best kept secrets. It was not until the following February that news of her birth was made known.

Scientists produced her by inserting DNA from a single sheep cell into an egg and implanting it in a surrogate mother.

In America, President Bill Clinton set up a task force to examine the legal and ethical implications of cloning, but 25 years later the process has manifested itself in unexpected ways.

Quite apart from the medical research it engendered into Parkinsons Disease and other conditions, it spawned an industry in pet cloning for the benefit of people who cannot bear to say goodbye to a loved animal.

Many people will pay to get a copy of their pet. Companies in America and South Korea have been specialising in this since 2001, said Dr Clarke. The first dog to be cloned was an Afghan hound.

But the same technology is also being used for something of real use, in the cloning of sniffer dogs that are used to search out explosives or drugs. Only a very small number usually make the grade, but Korean scientists managed to clone a golden Labrador retriever that was renowned for its sniffing abilities, and made several clones of it.

Not everyone likes the idea of that, but its clear that good can come from cloning.

Human closing, however, would likely remain beyond the pale, he said. In theory its completely possible, but no-one has done it and most people would consider it totally unethical.

Opinion was divided when Dolly the cloned sheep apparently named after the singer Dolly Parton was revealed to the world. Critics feared that the technique could be used to artificially produce humans, a prospect described by Dr Ian Wilmut, who led the team of scientists behind the project, as repugnant as well as illegal.

But he said the work would enable us to study genetic diseases for which there is presently no cure.

Many animal rights activists were horrified at the development, and the Church of Scotland said that while the work was fascinating, it had reservations about the implications.

Support The Yorkshire Post and become a subscriber today. Your subscription will help us to continue to bring quality news to the people of Yorkshire. In return, youll see fewer ads on site, get free access to our app and receive exclusive members-only offers. Click here to subscribe.

Read more:
25 years on, what is the legacy of Dolly the Sheep, and what future for GM food? - Yorkshire Post

The size of the global Canine Stem Cell Therapy market is expected to grow in the forecast period from 2020 to 2027, with a CAGR of XX. x% over the forecast period from 2020 to 2027 and is expected to reach XXX. X million by 2027, starting at XXX. X million in 2019.

A new informative report on the global Canine Stem Cell Therapy market titled as, Canine Stem Cell Therapy has recently published by Global Market Vision to its humongous database which helps to shape the future of the businesses by making well-informed business decisions. It offers a comprehensive analysis of various business aspects such as global market trends, recent technological advancements, market shares, size, and new innovations. Furthermore, this analytical data has been compiled through data exploratory techniques such as primary and secondary research. Moreover, an expert team of researchers throws light on various static as well as dynamic aspects of the global Canine Stem Cell Therapy market.

For Sample Copy of this Reports: https://www.globalmarketvision.com/sample_request/23873

The report presents a thorough overview of the competitive landscape of the global Canine Stem Cell Therapy Market and the detailed business profiles of the markets notable players. Threats and weaknesses of leading companies are measured by the analysts in the report by using industry-standard tools such as Porters five force analysis and SWOT analysis. The Canine Stem Cell Therapy Market report covers all key parameters such as product innovation, market strategy for leading companies, Canine Stem Cell Therapy market share, revenue generation, the latest research and development and market expert perspectives.

Some of the key players profiled in the Canine Stem Cell Therapy market include: VETSTEM BIOPHARMA

Cell Therapy Sciences

Regeneus

Aratana Therapeutics

Medivet Biologics

Okyanos

Vetbiologics

VetMatrix

Magellan Stem Cells

ANIMAL CELL THERAPIES

Stemcellvet

The main players in the Canine Stem Cell Therapy market are studies, and their strategies are analyzed to arrive at competitive prospects, current growth strategies and potential for expansion. In addition, the competitive landscape is due to the presence of market suppliers, numerous sales channels and revenue options. Contributions from industry experts as well as market leaders are an important factor in this study. Parents market trends, micro and macroeconomic factors, government stipulations and consumer dynamics are also studied in the writing of this report.Global Canine Stem Cell Therapy Market Segmentation:

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):Allogeneic Stem Cells

Autologous Stem cells

Application Coverage (Market Size & Forecast, Consumer Distribution):Veterinary Hospitals

Veterinary Clinics

Veterinary Research Institutes

Regions Covered in the Global Canine Stem Cell Therapy Market:

The Middle East and Africa

North America

South America

Europe

Asia-Pacific

Get Special Discount: https://www.globalmarketvision.com/check-discount/23873

Scope of the report: This report describes the global Canine Stem Cell Therapy market, in particular in North America, South America, Africa, Europe and Asia-Pacific, and the Middle East. This report segments the market based on producers, regions, type and use. In the next time, Canine Stem Cell Therapy will have good demand, although the value may fluctuate due to the rapid transformation in the availability of raw materials and other resources.

Regionally, this market has been inspected across various regions such as North America, Latin America, Middle East, Asia-Pacific, Africa, and Europe on the basis of productivity and manufacturing base. Some significant key players have been profiled in this research report to get an overview and strategies carried out by them. Degree of competition has been given by analyzing the global Canine Stem Cell Therapy market at domestic as well as a global platform. This global Canine Stem Cell Therapy market has been examined through industry analysis techniques such as SWOT and Porters five techniques.

Table of Content

1 Overview of the Canine Stem Cell Therapy market

2 Market competition by manufacturers

3 Production capacity by region 3 Production capacity by region

4 World consumption of Canine Stem Cell Therapy by region

5 Production, Turnover, Price trend by Type

6 Global Canine Stem Cell Therapy Market Analysis by Application

7 Company Profiles and Key Figures in Canine Stem Cell Therapy Business

8 Canine Stem Cell Therapy Manufacturing Cost Analysis

9 Marketing Channel, Distributors and Customers

10 Market Dynamics

11 Production and Supply Forecast

12 Consumption and demand forecasts

13 Forecast by type and by application (2021-2026)

14 Research and conclusion

15 Methodology and data source

Continuous

Place a Direct Order Of this Report: https://www.globalmarketvision.com/checkout/?currency=USD&type=single_user_license&report_id=23873

For Any special requirements about this report, please let us know and we can provide custom reports.

Note In order to provide a more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Excerpt from:
Canine Stem Cell Therapy Market to Eyewitness Massive Growth by 2027: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics -...

Dr. Sen-itiroh Hakomori couldnt leave his lab work alone. He would often log 13-hour days, seven days a week, and even spend some time at his job on Christmas morning, intensely focused on his glycosphingolipid medical and biochemical research.

I realized fairly recently that all of the cells are just like a pet. You have to check up on them and make sure that things are going well because theyre alive, said his daughter Naoko Vaughn. As children, we did not understand why he went to work every single day. I realized that he had to.

Vaughns father, who she said had a heart of gold and would help anybody, died of natural causes at the age of 91 on Nov. 10 at his home on Mercer Island.

Roger Laine, a colleague and friend who was the last professor to visit Hakomori, said that he was truly a pioneering scientist in glycobiology, a field in which he spent seven decades participating in groundbreaking studies.

He worked most of his career showing differences between cancer cells and normal cells that could be targeted for therapy. If you asked him what was his goal in life, he would answer, cure cancer, said Laine, a professor, scientist and researcher at Louisiana State University.

Hakomori is survived by his wife, Mitsuko (they were married for 74 years); Vaughn; sons, Yoichiro and Kenjiro; four grandchildren and two great-grandchildren; two brothers and a sister.

A native of Japan, professor Hakomori made crucial contributions to new cancer-cell studies at the Cancer Research Institute at Tohoku Pharmaceutical University, and continued his vast research in the field when the family immigrated to the United States to the Boston area.

The family moved from Boston to Bellevue in the late 1960s and set up their new home on Mercer Island 46 years ago. Hakomori relocated his family to the Pacific Northwest to become involved with the Fred Hutchinson Cancer Research Center, and served as University of Washington professor of pathobiology and professor of microbiology. He was named a UW professor emeritus of pathobiology and global health in 2006.

Hakomori retired at the age of 88, finishing his career working at the Pacific Northwest Cancer Center in Seattle. During a celebration in Japan three years ago, Hakomori who was a member of the prestigious National Academy of Sciences spoke to the attendees and noted, We are all globally connected with research and science.

His two sons reflected on their fathers vital contribution to their lives.

Dad was passionate about his work and a great mentor to many of his younger colleagues. He has inspired me to try to emulate that passion in the work I do as an architect and professor, said Yoichiro.

Added Kenjiro: Dad taught me by example to work hard on trying to find out and work on resolving research questions it is a lifelong passion.

Vaughn added that her father instilled a high-level work ethic in his children, telling them, Whatever you do, whatever you choose to do, whatever your passion is, you do it 120 percent.

Hakomori made a worldwide impact with his research and was nominated five times for the Nobel Prize in chemistry. He received numerous awards, including the Philip Levine Immunohematology Award, the Karl Meyer Award from the Society of Glycobiology and the Rosalind Kornfield Award for Lifetime Achievement in Glycobiology.

He published 585 articles in peer-reviewed journals, and a pair of his many major scientific achievements were methylation analysis of glycoconjugates with mass spectrometry, and cell adhesion based on carbohydrate-carbohydrate interaction, particularly through GSL clusters at the embryonic stem cell surface.

He was very honored in his work, and he did not do it for money. He was very much just trying to help, which is rare these days, said Vaughn, adding that a host of his students and colleagues from around the world are assembling a memorial for her father to be published in a glycosphingolipid journal.

He was just a wonderful person. I think the most important thing is his colleagues really admired him. He made them successful in their lives, Vaughn added.

When Sarah Spiegel was a graduate student, she was drawn to Hakomoris papers and reviews on the role of glycoconjugates in cancer. Those documents sparked her imagination and inspired her to pursue a career in sphingolipids, she wrote on the Evergreen Washelli Funeral Home & Cemetery memorial page.

He was a champion of advancing careers of young female scientists and his generous spirit influenced my generation and generations to come, said Spiegel, Ph.D., professor and chair in the Department of Biochemistry and Molecular Biology at the Virginia Commonwealth University School of Medicine. His legacy will live on through the works of countless researchers who continue working in the field of sphingolipids and many colleagues throughout the world will miss him tremendously.

In consideration of how we voice our opinions in the modern world, weve closed comments on our websites. We value the opinions of our readers and we encourage you to keep the conversation going.

Please feel free to share your story tips by emailing editor@mi-reporter.com.

To share your opinion for publication, submit a letter through our website https://www.mi-reporter.com/submit-letter/. Include your name, address and daytime phone number. (Well only publish your name and hometown.) We reserve the right to edit letters, but if you keep yours to 300 words or less, we wont ask you to shorten it.

The rest is here:
'He was very honored in his work' - Mercer Island Reporter

The report entitled Canine Stem Cell Therapy market also gives a detailed idea of various technologies used by the manufacturers and industry experts to enhance the technological intervention in this market. An in-depth study in terms of production, Canine Stem Cell Therapy market revenue share and price are also a major factor of focus in this report. The company profile section also focusses on companies planning expansions. This can be very well studied through regional segmentation as all the key market players play an important role in uplifting the region, they operate in.

Furthermore, the report also gives the factors that might hamper the market growth over the forecast period. The detailed report on Canine Stem Cell Therapy market gives its readers a summary of the market movements and helps them to analyze all the other factors that can affect the market.

Leading Players Covered in Canine Stem Cell Therapy Market Report

Request for Sample with Complete TOC and Figures & Graphs @ https://www.alltheresearch.com/sample-request/206

Market segmentationCanine Stem Cell Therapy market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type

By Application

Any query or need Customization? Ask here @ https://www.alltheresearch.com/customization/206

Highlights of the report:

Table of Content: Canine Stem Cell Therapy MarketChapter 1. Research Objective1.1 Objective, Definition & Scope1.2 Methodology1.2.1 Primary Research1.2.2 Secondary Research1.2.3 Market Forecast Estimation & Approach1.2.4 Assumptions & Assessments1.3 Insights and Growth Relevancy Mapping1.3.1 FABRIC Platform1.4 Data mining & efficiency

Chapter 2. Executive Summary2.1 Plastics Additives and Master Batches Market Overview2.2 Interconnectivity & Related markets2.3 Ecosystem Map2.4 Plastics Additives and Master Batches Market Business Segmentation2.5 Plastics Additives and Master Batches Market Geographic Segmentation2.6 Competition Outlook2.7 Key Statistics

Chapter 3. Strategic Analysis3.1 Plastics Additives and Master Batches Market Revenue Opportunities3.2 Cost Optimization3.3 Covid19 aftermath Analyst view3.4 Plastics Additives And Master Batches Market Digital Transformation

Chapter 4. Market Dynamics4.1 DROC4.1.1 Drivers4.1.2 Restraints4.1.3 Opportunities4.1.4 Challenges4.2 PEST Analysis4.2.1 Political4.2.2 Economic4.2.3 Social4.2.4 Technological4.3 Market Impacting Trends4.3.1 Positive Impact Trends4.3.2 Adverse Impact Trends4.4 Porters 5-force Analysis4.5 Market News By Segments4.5.1 Organic News4.5.2 Inorganic New

And More.

Speak to Our Industry Expert to get more information @ https://www.alltheresearch.com/speak-to-analyst/206

About Us

AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realise, that its not just sheer data-points, but the right analysis that creates a difference. While some clients were unhappy with the inconsistencies and inaccuracies of data, others expressed concerns over the experience in dealing with the research-firm. Also, same-data-for-all-business roles was making research redundant. We identified these gaps and built AllTheResearch to raise the standards of research support.

For All Your Research Needs, Reach Out to Us:

Contact Name: Rohan S.

Email: [emailprotected]

Phone: +1 (407) 768-2028

Read the original post:
Canine Stem Cell Therapy Market 2026 by Product Type, Applications, Manufacturers, Revenue, Price, Share and Growth Rate & Forecast -...

The pandemics toll on the research community

Given the collective pivot the globe took toward addressing the coronavirus pandemic, were dedicating a separate post to what we heard from scientists this yeartheir struggles and triumphs, frustrations and joys.

Aside from research on SARS-CoV-2 itself, the pandemic had huge effects on the scientific community. Tragically, the virus claimed the lives of a number of researchers. Lynika Strozier, whose hands of gold could extract DNA from small amounts of starting material and who identified numerous new species, was just 35 when she died of COVID-19. Paleobotanist Brian Axsmith died of COVID-19 at age 57. Paleontologist Robert Carroll, former Stanford University President Donald Kennedy, microbiologist Paul Matewele, former Babraham Institute Director Michael Wakelam, HIV researcher Gita Ramjee, and vascular biologist Stephen Schwartz were also among the 1.6 million people who have died from the disease this year.

While a considerable proportion of researchers found themselves struggling to do their work at times this year, others found themselves laid off or furloughed. Women in STEM appear to have taken the greatest hit to their productivity. Academic job opportunities shrunk and dont seem to have recovered to the hiring levels of past years.

Nevertheless, a survey of scientists has found the community resilient in the face of lockdowns and other restrictions, and the astounding accomplishments in the development of drugs, vaccines, diagnostics, and research techniques related to the coronavirus are a testament to researchers creativity and dedication. Scientists managed to keep their science afloat by turning their homes into wet labs and finding new ways to be productive. Scientific conferences went from cancelled or postponed to completely revamped as virtual events, with broadened inclusivity and fewer carbon emissions from travel.

With all eyes on SARS-CoV-2, it was easy to overlook other big events unleashed by mother nature. Wildfires burned up and down the US West Coast. In California, blazes damaged field sites and threatened astronomical observatories. And on the other side of the globe, in Australia, efforts to shore up vulnerable koala populations suffered, perhaps irreparably. Theres been so much research progress in recent years to try and improve the health status of these koala populations, Natasha Speight, a koala disease researcher and veterinarian at the University of Adelaide in South Australia, told The Scientist in January. It really is a setback to have so many lost from these bushfires.

Similarly, a park in Argentina where a long-term study of 20 groups of resident howler monkeys had been ongoing for decades saw at least five groups perish in fires this fall. All these groups that we found, I knew everything about them. I knew who was the son, the daughter, the mother. The first [few days] I was crying all the time, Martin Kowalewski, a primate ecologist and the director of the Estacin Biolgica Corrientes field station, told The Scientist. The fires were thought to have been started intentionally by ranchers to stimulate grassland growth, but they then burned out of control, decimating the reserve where the monkeys lived.

Electron microscopy image of mitochondria isolated from healthy human blood plasma

ALAIN THIERRY, INSERM

In February, scientists reported that they had found functioning mitochondria in peoples blood. Past studies had shown that mitochondrial DNA could be found in circulation, and at times the organelles might get released from cells in response to damage, but entire, respiring organelles in the blood of healthy individuals was a novel observation.

The whole thing surprises me, Joel Riley, who studies how mitochondria can stimulate inflammation at the University of Glasgow and wasnt involved in the study, told The Scientist at the time. We know that bits of mitochondria can get kicked out of cells through extracellular vesicles [when they are damaged], but whole mitochondriathats pretty cool. The next step is to figure out what the organelles are doing in circulation.

A 3-D reconstruction from histological slides (inset on right) of the newly discovered tubarial gland (yellow; ducts in light blue). The torus tubarius cartilage is colored dark blue and muscle is pink.

Humans continue to be full of anatomical surprises, and this year researchers added to our known components a set of salivary glands in the neck that they named the tubarial glands. The tissue, tucked behind the pharynx, likely went unnoticed because it is difficult to reach during surgery and was discovered with a combination of positron emission tomography (PET) and computed tomography (CT) that uses a radioactive tracer that binds to a prostate-specific membrane antigen (PSMA). Ordinarily, PSMA PET/CT is used to detect prostate cancer, but lead scientist Wouter Vogel, a radiation oncologist at the Netherlands Cancer Institute, told The Scientist in October, This scan is extremely sensitive for the salivary glands. So we can see more than ever before.

Although a perennial problem, a lack of equity in STEM gained renewed attention in 2020 as scientists advocated for inclusion, anti-racist action, and awareness of the forces that turn away people from underrepresented groups. Black in X, a collection of initiatives to raise the profile of Black scientists in various fields and support their careers, emerged after a racist incident in May between a Black birder and a white woman who wasnt following a canine leash law in New York Citys Central Park. Black in Neuro, Black in Astro, Black in Chem, and other groups have since organized virtual events and digital networking. Now that we can finally see each other, we can now support each other, Black in Micro co-organizer Ariangela Kozik, a postdoc at the University of Michigan, told The Scientist.

This year, several academic journals also came to recognize that their name-change policies could be harming transgender individuals. Cell Press, for instance, adopted a new policy that allows authors to change the name on their publications. It still requires issuing a correction, with the authors approval, which can reveal more information than authors might wish to provide. Theresa Tanenbaum, a computer scientist at the University of California, Irvine, who has worked on name-change guidance for journals, told The Scientist she advocates for publishers keeping a private record of name changes that would be released only when needed, such as in a legal case.

The first blood test to sample for blood biomarkers indicative of Alzheimers disease became available for physicians in October. C2N Diagnosticss test measures the ratio of two isoforms of the amyloid- protein, A42 and A40, and the presence of isoforms of apolipoprotein E (ApoE) associated with Alzheimers risk. If you asked me [five or ten] years ago if there would ever be a blood test for Alzheimers, I would have been very skeptical, Howard Fillit, the executive director and chief science officer of the Alzheimers Drug Discovery Foundation, which invested in C2Ns development of the test, told The Scientist. So the fact that this is on the market now is just amazing.

Because modern humans interbreeding with Neanderthals took place in Eurasia thousands of years ago, geneticists had assumed that individuals with African ancestry wouldnt have much Neanderthal DNA in their genomes. Not so. In a study that came out in January, researchers compared African genomes to the Neanderthal reference genome and found a lot more overlap than they had expectedabout 17 megabases.

This is still just one-third of whats found in the genomes of people with European and Asian ancestry, and likely represents the migration of people from Europe and Asia who carried with them to Africa the genetic legacy of their ancestors intermingling with Neanderthals.

Janet Kelso, a computational biologist at the Max Planck Institute for Evolutionary Anthropology who was not involved in the study, told The Scientist at the time, Whats surprising here is the amount. Its actually a larger proportion than I think people had imagined.

Read more from the original source:
The Biggest Science News of 2020 - The Scientist

Canine Stem Cell Therapy Market report shows the Industry Chain Structure as well as Macroeconomic Environment Analysis and Development Trend. The Canine Stem Cell Therapy Market report also provides the market impact and new opportunities created due to the COVID19/CORONA Virus catastrophe. The total market is further divided by company, by country, and by application/types for the competitive landscape analysis. The report then estimates 2020-2026 market development trends of Canine Stem Cell Therapy Industry.

TheCanine Stem Cell Therapy market report gives CAGR value, Industry Chains, Upstream, Geography, End-user, Application, Competitor analysis, SWOT Analysis, Sales, Revenue, Price, Gross Margin, Market Share, Import-Export, Trends and Forecast. The report also gives insight on entry and exit barriers of the industry.

Get Exclusive Sample of Report on Canine Stem Cell Therapy market @ https://www.alltheresearch.com/sample-request/206

The Canine Stem Cell Therapy Market Report Covers Major Players:

Canine Stem Cell Therapy Market Breakdown Data by its type

Canine Stem Cell Therapy Market Breakdown Data by its Application

Canine Stem Cell Therapy Consumption Breakdown Data by Region: North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam, Europe, Germany, France, UK, Italy, Russia, Rest of Europe, Central & South America, Brazil, Rest of South America, Middle East & Africa, GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa.

The Study Objectives of Canine Stem Cell Therapy Market Report are:

Any Customization required? Request here @ https://www.alltheresearch.com/customization/206

Major Points from Table of Contents:

Ask Your Queries to our Analyst regarding Canine Stem Cell Therapy Report @ https://www.alltheresearch.com/speak-to-analyst/206 Frequently Asked Questions:

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan

Email: [emailprotected]

Phone: +1 (407) 768-2028

Here is the original post:
Report On Canine Stem Cell Therapy Market to 2026: (Industry Insights, Company Overview and Investment Analysis) - Farming Sector

Following the harassment of Christian Cooper in Central Park in May 2020, Black birders created #BlackBirdersWeek to celebrate Black nature enthusiasts and highlight their belonging in outdoor spaces. Since then, dozens of campaigns have emerged to amplify and appreciate Black academics, scientists, and naturalists.

Next up is #BlackInMarineScienceWeek, running from November 29th to December 5th.Led by founder Dr. Tiara Moore and organizers Amani Webber-Schultz, Dr. Camille Gaynus, Carlee Jackson, Al Troutman, Jasmin Graham, Jeanette Davis, Kris Howard, Leslie Townsell, Kaylee Arnold, and Jaida Elcock, this week represents an opportunity for community building and improved representation.

There are few Black folks in ecology and even fewer in marine ecology, says Arnold, a science communicator and disease ecologist. The network that Ive gained through organizing this week is phenomenal. Meeting other Black marine scientists and showing that to the world, especially young Black folks, is a way to say we exist, were here. We have a full day dedicated to young kids, which is unique and exciting.

The organizers hope that the week will help normalize Black folks doing marine research, inspire younger generations, and remind everyone to check their preconceived notions.

"When I say I study sharks people seem concerned about my swimming or my hair, [and] sometimes respond with 'Oh, thats super interesting'... I dont know if that's because it's unusual for people to study sharks or because Im Black and I study sharks, recalls Elcock, an elasmobranch movement ecologist, science communicator, and co-founder of Minorities in Shark Science. Science is for everybody. People say there isn't diversity because [Black] people arent interested... thats clearly not true theres a whole week dedicated [to it]."

Discussion this week will address the fact that exclusion, not lack of interest, led to todays lack of representation. Centuries of segregation and underinvestment in Black neighborhood pools led to, and are perpetuated by, these incorrect and harmful ideas.

My grandparents and my mom said there were just no pools for her to go to... I had a very different experience. Despite people trying to push us out of the water and science, we persevered, and now we get to break down those stereotypes, notes Arnold.

Black in Marine Science Week is here to do just that, showcasing organizers and participants from every imaginable marine science niche, all shaping how society views the oceans and its inhabitants.

There's more Black folks than even we know and are showcasing. I hope that if the media picks up on the number of us as well, and has better representation. Seminar series are extremely white, and now you have a resource of people you can invite instead, emphasizes Arnold, pointing to the necessity of non-Black marine scientists to step up and ensure representation continues beyond this joyous and educational week.

More:
Exosomes act as messengers and decoys to save healthy cells from viral infection - Massive Science

MSPhotographic/Getty Images

Most kids with peanut allergies do not outgrow them. But, with a little help, some might be able to better tolerate accidental exposures.

In January, the Food and Drug Administration approved Palforzia, a new drug designed to help kids who are allergic to peanuts react better, if they are accidentally exposed.

"Because there is no cure, allergic individuals must strictly avoid exposure to prevent severe and potentially life-threatening reactions," Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research said at the time in a news release. "When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions."

Palforzia is not designed to be administered during an allergic reaction, instead it works as an allergy exposure therapy: children ages 4 through 17 receive daily doses of peanut powder under clinical supervision, and slowly up-dose it over time.

In clinical trials, the strategy worked well, but not perfectly. When peanut-allergic kids were fed 600 milligrams of peanut protein, 67.2% of Palforzia recipients who'd been using the medication for six months tolerated it, while only 4% of the control group did.

View post:
The 11 most mind-blowing health discoveries and innovations of 2020 - Business Insider - Business Insider

The alternative protein market is on fire right now, estimated to beworth approximately $2.2Bn, and cultivated meat is expected to play an important role in the shift from traditional meat products. Experienced scientists are engaging in so called cellular agriculture with the aim of reducing animal-based agricultures negative impact on both the planet and the suffering of animals and at the same time feeding a growing population.

It may take a while for consumers to accept the idea of growing meat in a lab rather than on a farm, but withincreasing concerns over food safety and securitythere is an ongoing shift in perception and priorities which is feeding the growth in cultivated meat development.

However, not everyone is as positive about the meat of the future. Animal rights activists such asClean Meat Hoaxplay a part in the resistance, but those with the biggest stake (steak?) are livestock farmers, with collectives such as theEuropean Livestock Voicedetermined to give consumers another perspective on the industry.

Here at Trellis Road, were of course following the startups and the development in this area closely. In this post we have summarized the startups across different subsectors to provide a snapshot of the state of the space.

A couple of things to note before diving in:

In the graphic below weve looked at the cultivated meat landscape based on two key groups of startups; the ones primarily focusing on producing the actual meat and the ones focused on enabling technologies.

Looking at the companies focused on producing the actual meat it is evident that beef has for long been the most attractive meat type to focus on, with 14 companies in the category compared to only two focused on chicken and four focused on pork, probably becauseindustrial beef production is the worst for the environment, so eliminating it with cultivated alternatives would make the biggest impact. In addition, the higher price point for beef makes price parity for a cultivated product at some point in the future more likely than it might be for cheaper meat types such as pork and chicken.

In the group of startups focusing on enabling technologies the biggest subcategory is Cell Culture Media, where 2019 showed a real increase with a whole of eight new startups. This might be seen as the industry now being developed enough to show growing demand for cell culture media, and weve also heard multiple founders state that they started working on cultivated meat products only to realise the cost and challenges related to the media, including making it truly animal-free. Another category that judging by this data has gained more interest in the later years is Scaffolding and Structure where four new startups has emerged since 2019.

Looking at it from a geographical standpoint we can see that North America and Europe dominates the industry; there are 25 companies based in North America, 23 in Europe and only ten in Asia as well as an additional ten from other parts of the world. Two countries that stands out as being a little extra relevant are Israel and the Netherlands; Israel having five startups in the sector despite only having 9 million inhabitants and the Netherlands having four startups in the sector despite only having 17 million inhabitants.

Heres the full list in alphabetical order:

Aleph Farms(Israel, 2016, beef) this crew are planning on cultivating their steaks in space; their ideas are literally out of this world (famous for getting the first ever head of a government to try cultivated meat)

Alife Foods(Germany, 2019, beef) consumer-first and product-orientated, working on cultivated meat processing, refinement and branding

Ants Innovate(Singapore, 2020, mixed/unspecified) focused on integrating muscle tissues, and developing healthier formulations for premium cultured meat products

Appleton Meats(Canada, 2016, beef) currently working on scaling up the production of clean ground beef, to serve the Canadian cellular agricultural market before expanding into the US

Artemys Foods(US, 2019, mixed/unspecified) working in the pursuit of guilt-free meat and a world without intensive animal agriculture

ArtMeat(Russia, 2019, other meats) cultivating horse and sturgeon cells, with a plan to bring products to market in 2023

Balletic Foods(US, 2017, mixed/unspecified) currently operating in stealth mode, working on bringing cultured meat to the masses

Because Animals(US, 2019, pet food) creators of the worlds first cultured meat pet food, a cat treat made from cultured mouse, and now working on a cultured rabbit dog treat

BioTech Foods(Spain, 2017, mixed/unspecified) its brand, Ethicameat, covers a range of cultured meat products which are high in protein, fat-free and antibiotic-free

BioBQ(US, 2018, beef) located in the land of true barbecue, this brand aims to be the first to offer cultivated beef jerky and beef brisket

BioFood Systems(Israel, 2018, beef) currently in stealth mode, this company has a patented process to cultivate bovine stem cells using an animal-free cell culture media

Brunocell(Italy, 2017, mixed/unspecified) finances and manages cell-based research projects

Cell Farm Food Tech(Argentina, 2019, beef) Latin Americas first cultured meat startup, it has a proprietary stem cell bank with the best Argentine bovine genetics

Cellular Agriculture Ltd(UK, 2016, mixed/unspecified) this companys tech sits at a footprint 200x smaller than incumbent bioprocess and at a 70% reduction in operational cost

Clear Meat(India, 2018, mixed/unspecified) Indias first eco-friendly, nutritious and affordable meat initiative (they claim to have reached price parity with conventional chicken during trials)

Cubiq Foods(Spain, 2018, fats) develops and produces cultivated fats from animal cells, with a whole host of health benefits

Fork & Goode(US, 2018, pork) a spinoff startup from cellular agricultural biomaterial company Modern Meadow, focused on cultivated pork products

Future Meat Technologies(Israel, 2017, chicken) these guys have already achieved a chicken kebab prototype

Gaia Foods(Singapore, 2019, beef) vertically-integrated cultured red meat producers

Gourmey(France, 2019, other meats) oh so French, this brands first project was a cultured foie gras produced from natural duck cells, no force-feeding allowed

Heuros(Australia, 2017, mixed/unspecified) this companys products are made without genetic engineering, so products can be sold as GM free

HigherSteaks(UK, 2018, pork) focused on pork products, and launched the worlds first lab-grown bacon and lab-grown pork belly in July this year

Hoxton Farms(UK, 2020, fats) just scooped the food & drink category award at The Royal Society of Chemistrys Emerging Technologies Competition 2020 for its work in speciality fats

Innocent Meat(Germany, , 2018, mixed/unspecified) all about efficiency (unsurprising), with fast growth cycles, media volume reduction and waste elimination

Integriculture(Japan, 2015, beef) part of the Shojinmeat Project, a non-profit which was founded to engage and inform people about cultured meat and allow them to grow it at home!

JUST (aka Eat Just & now GOOD Meat)(US, 2011, beef) best known for its work in plant-based eggs, but also working on cell-based Wagyu beef as a side hustle and now world-famous for being the first cultured-meat to get government regulatory approval (for its cultured chicken bites) and claims the title of first commercial sale of cultured meat

Lab Farm Foods(US, 2019, mixed/unspecified) just announced as part of Merck KGaAs 2020 Accelerator Cohort, alongside membership in NYU Langones Biolabs Incubator

Meatable(Netherlands, 2018, beef) can make the same amount of meat in three weeks as would take a cow three years to grow

Memphis Meats(US, 2015, mixed/unspecified) one of the originals, these guys raised a mind-blowing $161M at the start of 2020 to continue developing their chicken, beef and duck prototypes

Mirai Foods(Switzerland, 2019, beef) initially working on minced beef and covers the entire value chain, from R&D to distribution

Mission Barns(US, 2018, pork) creators of Mission Pork Bacon and Mission Fat, both of which are kosher

Mosa Meat(Netherlands, 2015, beef) made the worlds first cell-based beef burger and closed a $55M series B round in September 2020

Mzansi Meat(South Africa, 2020, beef) Africas first cell-based meat startup, with a focus on developing products which are specifically tailored for traditional African dishes such as braai

New Age Meats(US, 2018, pork) this team developed the first lab-grown sausage, which is smoky, savoury and tastes like breakfast

Orbillion Bio(US, 2019, beef) working on heritage meats from premium heirloom breeds, with a farm-to-table story

Peace of Meat(Belgium, 2019, fats) developers of cultured fat to add taste and texture to plant-based ingredients. Soon to be acquired by MeaTech.

Pristine Pet Food(US, 2020, pet food) trying to revolutionise the way pet food is made, eliminating by-products and reducing disease rates

SingCell(Singapore, 2020, mixed/unspecified) stem cell manufacturers offering integrated testing, process development and GMP manufacturing solutions

Supermeat(Israel, 2015, chicken) working to develop meal-ready cultured chicken, debuted worlds first cultured chicken tasting restaurant (non-commercial)

Vow Food(Australia, 2019, other meats) working on lab-grown kangaroo meat, most Australian thing ever

Wild Earth(US, 2017, pet food) focused on koji-based protein using their fermentation platform, alongside cultivated mouse meat, both for pet food. Co-founder Ryan Bethencourt is one of the investors behind Sustainable Food Ventures

Heres the full list in alphabetical order:

Agulos Biotech(US, 2017, cell culture media) developing Simulated Platelet Lysate (porcine), a replacement for FBS

Back of the Yards Algae Sciences(US, 2018, cell culture media) algae is hot right now, and this team is working on algae-based cell culture media

Biftek(Turkey, 2018, cell culture media) creators of a novel culture medium supplement formulation to grow muscle stem cells, which dramatically reduces production costs when compared to a conventional FBS

Biocellion(US, 2013, software) developers of cell culture modelling software for virtual experiments, so businesses can test theories and products before starting on laboratory experiments

Boston Meats(US, 2020, scaffolding and structure) committed to creating the true texture of meat through a sustainable and scalable process

Cellivate Technologies(Singapore, 2019, cell culture media) a spin-off from the National University of Singapore, and has patented a nanotechnology which enables cells to better adhere and accelerates their growth while maintaining vital cellular markers

Cell-tainer Biotech BV(Netherlands, 2015, bioreactors) building bioreactors for cell culture and microbial fermentation; currently working with Mosa Meat

CellulaREvolution(UK, 2019, bioreactors) developers of enabling technologies, including a peptide coating which increases cell proliferation in serum-free conditions, and a bioreactor capable of serum-free continuous production of adherent cells

Core Biogenesis(France, 2020, cell culture media) next-generation recombinant protein production technologies

Cultured Blood(Netherlands, 2019, cell culture media) exactly as youd expect from the company name, these guys are aiming to produce a viable artificial blood circulation system

Defined Bioscience Inc(US, 2019, cell culture media) developing cell culture reagents, growth medium and kits to grow high quality stem cells and iPSC derived cells and organoids

Excell(US, 2019, scaffolding and structure) working on mycelium scaffolds for cultured meat, tissue engineering and biomedical applications

Future Fields(Canada, 2017, cell culture media) this companys end goal is to enable the commercialisation of the cultured meat industry through providing customised growth media, growth factors and enabling solutions at disruptive costs

Incuvers(Canada, 2018, incubators) inventors of the worlds first smart incubator, complete with virtual lab assistant for live cell imaging and monitoring

Luyef Biotechnologies(Chile, 2019, cell culture media) B2B R&D to support the cultivated meat industry

Matrix Meats(US, 2019, scaffolding and structure) we hope they dont get a glitch in their nanofiber scaffolds, which support cell proliferation

MeaTech(Israel, 2019, 3D printers) focused on 3D printing, and just invested 1M in Peace of Meat to help develop its technologies

Multus Media(UK, 2019, cell culture media) creators of an animal-free serum substitute; its growth media will allow customers to produce competitively-priced, high quality meat products

Myoworks(India, 2017, scaffolding and structure) looking to manufacture and supply scaffolds for the global cultivated meat industry

Novel Farms(US, 2020, scaffolding and structure) producing cruelty-free, marbled cell-based meat delicacies for ethical foodies

NUProtein Co Ltd(Japan, 2019, cell culture media) developers of wheat germ-based cell-free proteins

ORF Genetics(Iceland, 2001, cell culture media) global leaders in barley biotech, received a 2.5M award from the Grant Management Services of the European Commission earlier this year for R&D of animal-like growth factors

Ospin Modular Bioprocessing(Germany, 2014, bioreactors) working on bioreactor systems for cultured meat and tissue engineering

SunP Biotech(China and US, 2014, 3D printers) working on bioprinters and bioink for cultivated meat production

TeOra(Singapore, 2019, cell culture media) producing cultivated meat growth factors with a microbial optimisation platform

Tiamat Sciences(Belgium, , 2019, cell culture media) manufacturers of plant-based growth factors and proteins for cellular agriculture

Vivax Bio(US, 2018, 3D printers) focused on 3D bioprinting solutions for cultivated meat

This post originally appeared on Medium,read it here. It is reprinted here with permission from the author.

Lead image of GOOD MEAT at 1880 Restaurant in Singapore courtesy of Eat Just / GOOD Meat.

More:
Cultured Protein: A Guide To Every Cell-Based Meat Startup In The World Right Now - Green Queen Media